Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma® Life Science and Axiogenesis Collaborate

Published: Wednesday, August 01, 2012
Last Updated: Wednesday, August 01, 2012
Bookmark and Share
Companies to market more predictive iPSC-based assays and services for preclinical cardiotoxicity screening.

Sigma-Aldrich® Corporation announced that Sigma Life Science, its innovative biological products and services research business, has signed an agreement with Axiogenesis to market mouse induced pluripotent stem (iPS) cell-derived cardiomyocytes and smooth muscle cells. In contrast to short-lived, tissue-derived primary cells that predominate preclinical drug discovery and cardiotoxicity screens, Sigma Life Science and Axiogenesis' iPS cell-derived primary cells enable long-term studies that are necessary to more accurately predict cardiotoxicity. These derived cell types are available as ready-to-order cells, application-specific kits and custom services catering to novice and expert users. Details are available at www.sigma.com/cardiac.

"Costly drug candidate failures in clinical trials are most frequently caused by cardiac safety issues," said John Listello, Market Segment Manager of Stem Cell Research and Regenerative Medicine at Sigma Life Science. "Early identification of these cardiac liabilities is hindered by the lack of reliable and standardized cardiomyocyte cell culture models.

"Avoiding clinical trial failures is a principle driver for the Sigma/Axiogenesis collaboration, which provides drug developers large numbers of these consistent cell culture models. This partnership deepens Sigma Life Science's commitment to alleviate critical deficiencies in ADME/Toxicology screening and preclinical development through application of iPS cell technology recently licensed from Kyoto University, CompoZr® Zinc Finger Nucleases, and the SAGEspeed(TM) Custom Animal Model Development program."

Cardiomyocytes for research and screening purposes are commonly isolated from available animal and patient tissue. The predictive utility of tissue-derived cardiomyocyte pools is limited because they do not spontaneously beat, gradually dedifferentiate into fetal-like physiological states, and contain a high percentage of contaminating cell types, such as fibroblasts that can rapidly override the culture. As a result, many critical long-term studies that could identify cardiac liabilities prior to clinical trials cannot be performed.

"In contrast, Axiogenesis' iPS cell-derived cardiomyocytes enable long-term studies that are impossible to perform in tissue-derived samples, such as accumulation studies that examine the effects of chronic dosing for several weeks at physiologically relevant, picogram levels. Accumulation patterns from such long-term studies can identify toxic compounds whose toxicity was not detectable through alternative experiments," concludes Listello.

Cardiomyocytes derived from Axiogenesis' iPS cell lines maintain physiologically-relevant biology, purity, and spontaneous beating for longer than 28 days. These iPS-cell derived cardiomyocytes are validated for functional electrophysiology, calcium-flux and calcium-wave analysis, cardiac cytotoxicity, mitochondrial metabolism, and as a disease model for cardiac hypertrophy.

Sigma Life Science's existing stem cell product portfolio includes custom iPS cell CompoZr ZFN-mediated genetic engineering, serum-free cell culture products, cell culture media, 3D matrices, growth factors, and antibodies, providing uniquely comprehensive support for iPS cell-related research. Sigma Life Science acquired a worldwide license to Kyoto University's iPS cell patent portfolio in February.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma® Life Science Creates World’s First Knock-in Rats using Zinc Finger Nuclease Technology
Scientific breakthrough by Sigma Advanced Genetic Engineering (SAGE™) Labs enables creation of more sophisticated models of human disease.
Tuesday, December 14, 2010
Scientific News
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Arms Race with a Superbug
Scientists have discovered that increased risk of superbug infection can be directly casued by immune system response to invading bacteria.
Genes Essential to Life Discovered
Genes critical for life are discovered in humans and mice as part of large-scale phenotyping study.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
Manipulation of Liquid Crystals Could Help Control Drug-Delivery Process
Computer modeling, real-world testing yields new method.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!